Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dicks Sporting Goods Inc (DKS) vs Novavax Inc (NVAX) Price & Performance

Dicks Sporting Goods IncTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Dicks Sporting Goods Inc vs Novavax Inc — how do they compare? Dicks Sporting Goods Inc trades at $135.72 (market cap $13.26B), while Novavax Inc trades at $12.54 (market cap $1.82B). The key difference: Dicks Sporting Goods Inc is far larger — about 7.3× Novavax Inc's market cap, and Dicks Sporting Goods Inc pays a 3.71% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dicks Sporting Goods Inc for 19 Days and Novavax Inc for 59 Days on average.

DKSNVAX
Market Cap
$13.26B$1.82B
Volume
2,292,0356,198,505
Sector
Consumer CyclicalHealth
52-Week High
$239.17$12.56
52-Week Low
$121.15$6.22
Typical Hold Time
19 Days59 Days
Enterprise Value
$20.31B$1.39B
Dividend Yield
3.71%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dicks Sporting Goods Inc

DICK'S Sporting Goods (DKS) trades at $134.91, up 2.84% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains solid fundamentals with a P/E of 14.86 and ROE of 18.47%, though recent earnings showed a Q2 2026 miss. Analyst consensus remains strongly positive with 56.9% buy ratings and a $153.30 price target, representing 13.6% upside potential from current levels.

While facing securities litigation headwinds, DKS demonstrates operational strength with $1.31B operating cash flow and consistent dividend payments. The stock offers value with attractive valuation metrics, but investors should monitor the ongoing class action lawsuits and potential impact on near-term sentiment despite the fundamentally sound business model.

Novavax Inc

Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.

Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DKS

No sentiment data available yet.

NVAX
59% Buy41% Sell
Avg holding period · 59 Days

Top news

Latest headlines on both assets

About Dicks Sporting Goods Inc

Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.

Read more on DKS →

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX →